A new study led by Tata Memorial Centre (TMC) and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) highlights the unaffordability of immunotherapy for head and neck cancers in India and other countries. Six months of pembrolizumab costs nearly ₹61 lakh in India — 80 times the average monthly income. Even cheaper options like nivolumab remain out of reach.